Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Most patients with major depressive disorder (MDD) do not reach symptom remission. These patients with residual symptoms have worse function and worse prognosis than those who remit. Several augmentation and combination treatments are used to either increase the chances of achieving remission or to eliminate/minimize residual depressive symptoms. Evidence for these pharmacological approaches rests primarily on open, uncontrolled studies, and there are clearly not enough controlled studies. Clinicians should carefully weigh these different treatment options to increase their patients’ chances of achieving and sustaining remission from depression. This paper will review the pertinent studies and will propose a novel approach to improve practice involving the use of augmentation or combination strategies at the outset of initial treatment to primarily enhance the chances of remission through synergy and/or a broader spectrum of action. This novel approach could potentially enhance retention and/or increase remission rates since the lack of response with antidepressant monotherapy may lead many depressed patients with little or no benefit to drop out of treatment, precluding the subsequent use of augmentation or combination strategies altogether. In addition, the emergence of certain side-effects (e.g., agitation, insomnia) or the persistence of some initial baseline symptoms (e.g., anxiety, insomnia) may lead to premature discontinuation from monotherapy in the absence of concomitant use of augmenting pharmacological options targeting these symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unützer, J., Katon, W., Callahan, C. M., Williams, Jr., Hunkeler, E., Harpole, L., Hoffing, M., Della Penna, R. D., Noël, P. H., Lin, E. H. B., et al. (2002) · JAMA · doi:10.1001/jama.288.22.2836 · Cited by 2,405
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 1×
“Treatment-resistant depression typically refers to the presence of an inadequate clinical response following adequate antidepressant therapy among patients suffering from major depressive disorder (MDD). While the more traditional view of treatment resistance has focused on nonresponse (i.e., patients with minimal or…”
BackgroundKeller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331 · cited 1×
“Beginning with a combination of depression-targeted psychotherapy and medication substantially increases remission rates in clinically depressed patient [”
BackgroundSelf-citationSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationDEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Self-citationResidual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791 · cited 1×
“Patients with MDD who do not achieve complete symptom remission are particularly vulnerable to relapse [”
BackgroundPrevention of Recurrent Depression With Cognitive Behavioral Therapy: Preliminary Findings
Fava, G. A., Rafanelli, C., Grandi, S., Conti, S., & Belluardo, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.816 · Cited by 491
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470
Self-citationJudd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1501 · Cited by 458
Cited by
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citationMarcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
“inadequate antidepressant response or to increase the chance of achieving remission.(2) In particular, atypical antipsychotics”
BackgroundRush, A. J., Trivedi, M. H., Stewart, J. W., Nierenberg, A. A., Fava, M., Kurian, B. T., Warden, D., Morris, D. W., Luther, J. F., Husain, M. M., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111645 · Cited by 372
Self-citationThase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332
Self-citationPapakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Folate in Depression: Efficacy, Safety, Differences in Formulations, and Clinical Issues
Fava, M., & Mischoulon, D. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8157su1c.03 · Cited by 301
Self-citationPapakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
Self-citationBerlim, M. T., & Turecki, G. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.009 · Cited by 249
“Treatment outcome What constitutes inadequate response to the treatment of a MDE has been an object of considerable debate, but most experts nowadays probably would argue that it is the failure to achieve remission (Keller, 2005; Fava and Rush, 2006).”
BackgroundRuhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1203 · Cited by 230
The Neuronal Transporter Gene SLC6A15 Confers Risk to Major Depression
Kohli, M. A., Lucae, S., Saemann, P. G., Schmidt, M. V., Demirkan, A., Hek, K., Czamara, D., Alexander, M., Salyakina, D., Ripke, S., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.005 · Cited by 228
Perlis, R. H., Iosifescu, D. V., Castro, V. M., Murphy, S. N., Gainer, V. S., Minnier, J., Cai, T., Goryachev, S., Zeng, Q., Gallagher, P. J., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711000997 · Cited by 193
“…resistant depression (TRD), typically defined as a failure to respond to at least two adequate trials of medication or other somatic therapies (Fava & Rush, 2006 ; Rush et al. 2006), contributes substantially to the disability and associated costs of MDD (Gibson et al. 2010) and may also be…”
BackgroundMethodAdaptation of dialectical behavior therapy skills training group for treatment-resistant depression
Harley, R., Sprich, S., Safren, S., Jacobo, M., & Fava, M. (2008) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0b013e318162aa3f · Cited by 184
“are consistent with clinical practice (Fava and Rush, 2006).”
BackgroundThe mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
Psychostimulants for depression
Candy, B., Jones, L., Williams, R., Tookman, A., & King, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006722.pub2 · Cited by 156
Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153
Insomnia and depression: a multifaceted interplay
Manber, R., & Chambers, A. S. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0066-1 · Cited by 134
“It is also well accepted by patients, many of whom have concerns about developing hypnotic dependence [ 59 ].”
BackgroundCarvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110
“In the past few decades, several agents have been tested for their augmentation effects in clinical trials of TRD (24, 25).”
BackgroundStrategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms
Kurian, B. T., Greer, T. L., & Trivedi, M. H. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.53 · Cited by 73
Fava, M., Targum, S. D., Nierenberg, A. A., Bleicher, L. S., Carter, T. A., Wedel, P. C., Hen, R., Gage, F. H., & Barlow, C. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.013 · Cited by 67
Self-citationPerahia, D. G. S., Quail, D., Desaiah, D., Montejo, A. L., & Schatzberg, A. F. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.07.001 · Cited by 64
Stahl, S. M. (2010) · CNS Spectrums · doi:10.1017/s1092852900027334 · Cited by 40
Stålsett, G., Gude, T., Rønnestad, M. H., & Monsen, J. T. (2012) · Psychotherapy Research · doi:10.1080/10503307.2012.692214 · Cited by 26
Metadata
- Authors
- Fava, M., & Rush, A. J.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2006
- Volume
- 75
- Issue
- 3
- Pages
- 139-153
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2034822289
- Cited by
- 151
- References
- 24
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.